Patients with primary open-angle glaucoma or ocular hypertension who received QLS-111 experienced lower IOP in two phase 2 trials, according to a press release from Qlaris Bio.
The Osprey and Apteryx studies of QLS-111, a topical formulation using the company’s ATP-sensitive potassium channel modulator platform that targets episcleral venous pressure, met all primary and secondary endpoints.
The masked, randomized Osprey study was designed to assess the safety, tolerability and IOP-lowering activity of QLS-111 in a range of doses compared with vehicle in 62 adult patients. The 0.015%